Navigation Links
Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
Date:9/11/2007

BEIJING, Sept. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading China-based biopharmaceutical company focusing on human vaccine development, announced today that it has commenced vaccination of volunteers for its Phase II clinical research study of its pandemic influenza H5N1 vaccine. The Phase II clinical trial is a randomized double-blind study to assess the safety and efficacy of the pandemic influenza H5N1 vaccine. The trial started with 400 adult volunteers vaccinated with Pandemic Influenza whole viron H5N1 Vaccine. The initial result from this study is expected to be available by the end of 2007.

As previously announced, Phase II clinical trial for the H5N1 vaccine were approved in April 2007 by the China State Food and Drug Administration (SFDA). The SFDA approval covers Phase Ib and II trials of the whole viron vaccine and Phase I and II trials of the split vaccine.

Phase Ib clinical trial with whole viron H5N1 vaccine and Phase I clinical trial with split H5N1 vaccine commenced in August 2007. The Company is making good progress on these trials.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com .

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. P
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., WEST PALM BEACH, Fla., Nov. 25 /PRNewswire-Fi...paired Americans, especially the 27 million living...ot be all that happy, says audiologist Cindy Beyer...A (Amex: EAR ), one of America,s largest hearing ...ve linked hearing loss to stress, frustration, and...
(Date:11/25/2009)... , HARBIN, China, Nov. 25 /PRNewswire-Asi...a Sky One Medical" or "the Company") (Nasdaq: CSK...pany developing and producing,over-the-counter dru...y,announced that the Company recently passed the C...aceutical and Biological Products ("ICPBP") examin...
(Date:11/25/2009)... , EAST BRUNSWICK, N.J., Nov. 25 /PRNewswire/ -...rer of direct digital Radiography ( ddR ) systems,...uired by a private Swiss Investor with a long term...rand. The acquisition included all assets and inte...ory. After 25 years of success and growth Swissray...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Swissray International Announces New Ownership 2Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 1Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 2Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 3Swine Flu Advice from Confused com 53410 1Swine Flu Advice from Confused com 53410 2Swine Flu Advice from Confused com 53410 3Benefits from upper airway surgery for sleep apnea found to equal CPAP 53407 1
... Phase I Report from Trial of Quadramet in Combina... Refractory Multiple Myeloma. , , LOS ANGELES, Fe...a radioactive medication that targets the bone, sp...caused by cancer that has metastasized or spread t...for the treatment of multiple myeloma alone and in...
...- , , PLYMOUTH MEETING, Pa., Feb. 10 Genaera Cor...g preliminary Phase 1b clinical data for trodusque...ive inhibitor of PTP1B and Genaera,s lead drug can...esity. Mr. Jack Armstrong, President and CEO of G...orts in an ascending multiple dose study of MSI-14...
Other Medicine Technology:Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results 2Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 2Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 3
(Date:11/28/2009)...eved to affect circadian rhythm, , ,... suggests that an internal body clock that goes on... bipolar disorder in children. , The finding r...of 152 children with bipolar disorder, which can m...40 children without the disorder. They linked vari...
(Date:11/27/2009)...ch firm Replikins Ltd. today issued its latest bio... It shows that the lethality of the virus has drop...us,s current outbreak in the spring of 2009 to res...1). The H1N1 infectivity count, however, remains i...) November 27, 2009 -- Biotech firm Replikins Ltd....
(Date:11/27/2009)..., France, Nov. 27 Team Garmin-Slip...am dedicated to ethical sporting and developing th...today that it will become Team Garmin-Transitions ...sponsor of the team. Transitions Optical is the wo...fering the most advanced photochromic technology i...
(Date:11/27/2009)...ented medical, economic burdens, study predicts ,...e number of people with diabetes in the United Sta...a new study predicts. , That would bring the to...disease, up from 23.7 million today. , , At the ...es will triple, the study also warns, rising from ...
(Date:11/27/2009)...alist manufacturers who use medical load cells at ... dollars by bringing in technology partner Flintec...f pro-active medical manufacturers are calling in ...their projects, ensuring that progress will not be...tially outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...e-FirstCall/ - The Westaim Corporation,announced t...l western,Canadian construction services companies...posed reorganization agreement dated on,October 3,...hin 14 days of the mailing of the information circ...
... combination that included folic acid and vitamin ...l risk of cancer, including breast cancer, among w...ding to a study in the November 5 issue of JAMA ....fortification of the food supply with folic acid (...
...VION,PHARMACEUTICALS, INC. (OTC Bulletin Board: VI...ference call on Thursday, November 6, 2008 to,disc...e call will begin at 8:30 a.m. Eastern Time., To ... start of the call. When prompted for a pass code,...
...the possibility of,a failed ceasefire and renewed ...us humanitarian situation in the Democratic Republ...carrying out urgently needed,distributions of ther...fighting reignites," said Pierre Willems, Internat...
...n insulin pump to manage diabetes is more convenie...jections. That much, physicians already know. , ...d their primary caregivers is an important questio... lives," says Dr. Max Stachura, director of the Me...
...articipation in Upcoming Investor Conferences in ...O, Nov. 4 Orexigen(R) Therapeutics,Inc. (Nasdaq: ...e treatment,of obesity and other central nervous s...uarter 2008 financial results,as well as upcoming ...
Other Medicine News:Health News:Folic acid, B vitamins do not appear to affect cancer risk 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis 2Health News:Impact of insulin pump under study 2Health News:Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008 2
...d has been developing diverse medical products for... have earned an outstanding reputation for innovat...lds internationally recognized brands include the ...o® medical sundry products, Bristoline® mi...
...llest nebulizer utilizing Vibrating Mesh Technolog...patients suffering from Asthma, COPD or other resp...product size and handy carrying case that is easil...elivery comparable to table-top compressor nebuliz...
...reg; Air Entrainment Nebulizers deliver particulat...onic secretion patients. For your convenience, The...ting supply of sterile water., ,The P30000N, for ... with a total flow range of 68-24 lpm. For your hi...
...y of medication as well as humidification, try Flo... closed dilution, high volume, continuous medicati...alation therapy to patients. Its 200 ml reservoir ...ulized medication delivery at 25 ml/hr. Particles ...
Medicine Products: